Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Ari Zimran, MD, Shoshana Revel-Vilk, MD, Deborah Elstein, PhD, Naama Arbel, Michal Becker-Cohen, MSc, Gaya Chicco, Jeff Szer, MB, BS, FRACP

Blood (2017) 130 (Supplement 1): 2101.

https://doi.org/10.1182/blood.V130.Suppl_1.2101.2101

Published: 2017

Journal Articles

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Ari Zimran, MD, Derlis Emilio Gonzalez-Rodriguez, MD, Aya Abrahamov, MD, Deborah Elstein, PhD, Rene Heitner, MD, Alona Paz, MD, Einat Brill-Almon, PhD, Raul Chertkoff, MD

Blood (2012) 120 (21): 2140.

https://doi.org/10.1182/blood.V120.21.2140.2140

Published: 2012

Journal Articles

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Rosa Ruchlemer, MD, Deborah Elstein, PhD, Eti Broide, Constantine Reinus, Hannah Maayaan, Ari Zimran, MD

Blood (2011) 118 (21): 1100.

https://doi.org/10.1182/blood.V118.21.1100.1100

Published: 2011

Journal Articles

Haplotype Block for Inflammatory Cytokine Gene Polymorphisms in Fabry Disease.

Deborah Elstein, PhD, Rachael Safyan, Catharina Whybra, MD, Michael Beck, MD, Gheona Altarescu, MD

Blood (2006) 108 (11): 3834.

https://doi.org/10.1182/blood.V108.11.3834.3834

Published: 2006

Journal Articles

Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease.

Ari Zimran, MD, Candida Fratazzi, MD, Robert Mensah, PhD, Deborah Elstein, PhD

Blood (2005) 106 (11): 3882.

https://doi.org/10.1182/blood.V106.11.3882.3882

Published: 2005

NARROW

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Haplotype Block for Inflammatory Cytokine Gene Polymorphisms in Fabry Disease.

Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease.

Email alerts

ASH Publications

American Society of Hematology

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Haplotype Block for Inflammatory Cytokine Gene Polymorphisms in Fabry Disease.

Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only